Summary by Futu AI
Recursion Pharmaceuticals, Inc. (Recursion) has announced the offering of 30,769,230 shares of its Class A common stock at a public offering price of $6.50 per share. The offering is filed under Rule 424(b)(5) with the Securities and Exchange Commission (SEC) and is detailed in the prospectus supplement dated June 26, 2024. The shares are listed on the Nasdaq Global Select Market under the symbol 'RXRX.' The last reported sale price of Recursion's Class A Common Stock on Nasdaq was $8.76 per share as of June 26, 2024. The underwriters for the offering are Goldman Sachs & Co. LLC, J.P. Morgan, and Allen & Company LLC, who have the option to purchase an additional 4,615,384 shares. The offering is expected to close on or about June 28, 2024. The net proceeds from the offering, estimated at approximately $188.9 million before expenses, are intended for the advancement of Recursion's preclinical and clinical programs, platform technologies, and for general corporate purposes, including potential strategic investments and acquisitions.
